Share on

Latin America Glycobiology Market Research Report - Segmented By Product, Application, End User & Country (Mexico, Brazil, Argentina, Chile & Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2023 to 2028)

Published: March, 2023
ID: 6750
Pages: 145
Formats: report pdf report excel report power bi report ppt

Latin America Glycobiology Market Size & Growth (2023 to 2028)

As per the research report, the size of the Latin America Glycobiology Market was valued at USD 83.61 million in 2023 and estimated to be growing at a CAGR of 12.5%, to reach USD 150.67 million by 2027 during the forecast period 2023 to 2028.

Increased financing for glycomics and proteomics research and substantial R&D expenditures by pharma and biotech businesses are likely to propel glycobiology industries in Latin America to new heights.

Biotechnology and pharmaceutical businesses aggressively invest in glycobiology and proteomics research and development to provide superior biological products.

Pharmaceutical and biotechnology R&D, as well as investments in the glycobiology market, are predicted to increase the demand for solutions for diseases like cancer.

Glycobiology is an appealing investment potential for multinational pharmaceutical and biotech companies. Furthermore, glycomic biomarkers have a wide range of uses in medication development and diagnostics for various disorders.

Furthermore, a significant amount of money is invested in developing its goods, and the approval of newly produced pharmaceuticals necessitates several regulatory steps. As a result, these products are quite costly.

Pharmaceutical companies are expanding their R&D investments, which means more drugs are being discovered and developed using glycomics.

Technological advancements in glycomics devices are a significant driver of market expansion. Furthermore, rising government investments in research and development and pharmaceutical and biotechnology companies' increased focus on innovative drug discovery are driving the growth of the Glycobiology market.

The Latin America glycobiology market's revenue growth is hampered by factors such as high production costs and a scarcity of experienced personnel.

In addition, as a result of the COVID pandemic, the world faces unprecedented operational and economic concerns. New coronavirus viruses will need to develop and commercialize appropriate treatment options.

In the approaching quarters of 2020 and 2021, these collective problems are expected to slow down industry and academic research on cancer and diabetic disorders. Furthermore, local governments are prioritizing healthcare resources to address COVID-19 pandemic problems, which are projected to impede glycobiology market growth in the short term.

This research report on the Latin America Glycobiology Market has been segmented and sub-segmented into the following categories:

By Product:

  • Enzymes
  • Instruments
  • Kits & Reagents

By Application:

  • Diagnostic
  • Drug Discovery
  • Oncology

By End User:

  • Academic Research Institutions
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations   

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, the Latin American glycobiology market is predicted to proliferate, owing to an increase in the number of research projects being undertaken in nations such as Mexico and Brazil. In addition, several non-profit and governmental organizations are offering research funding to academics and research laboratories to boost glycoscience research in glycobiology, which is projected to drive the Latin American glycobiology market forward.

The regional market has been pushed by the availability of well-established healthcare infrastructure and access to innovative products. Furthermore, there is an increase in the use of glycan in various cancers and increased government funding for glycobiology research, all of which contribute to the market's growth throughout the projection period.

The Mexico glycobiology market is expected to dominate the Latin American glycobiology market due to a large number of companies making a substantial contribution to the market's growth. These companies' primary tactics for long-term growth include new product launches, mergers and acquisitions, partnerships, and collaborations.

The Brazil glycobiology market is predicted to hold the most significant share of the Latin American Glycobiology market, following Mexico. However, the worldwide glycobiology market is expected to rise over the projection period due to increased product launches such as mass spectrometry devices, high-profile liquid chromatography (HPLC) devices, and others.

KEY MARKET PLAYERS

Prominent companies leading the Latin American Glycobiology Market profiled in the report are Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), Waters Corporation (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Bruker Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany).,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample